Answer
Teriflunomide selectively and reversibly inhibits dihydroorotate dehydrogenase, reducing proliferation of rapidly dividing cells dependent on new pyrimidine synthesis; its exact therapeutic mechanism in multiple sclerosis is not fully understood, but is mediated by reduced lymphocyte numbers.
Sources for this answer
- Teriflunomide 14 mg film-coated tabletsaxunio Pharma GmbH · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked